Office of the Secretary, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations, 24408 [2021-09562]
Download as PDF
<![CDATA[
24408
Federal Register / Vol. 86, No. 86 / Thursday, May 6, 2021 / Notices
Dated: May 3, 2021.
David W. Freeman,
Program Analyst,Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–09585 Filed 5–5–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Secretary, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations
National Institutes of Health,
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Office of the Secretary of
the Department of Health and Human
Services (HHS) is seeking nominations
for two individuals to serve as nonfederal public members on the Muscular
Dystrophy Coordinating Committee.
DATES: Nominations are due by 5:00
p.m. EDT on June 7, 2021.
ADDRESSES: Nominations must be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen
Nuckolls, Ph.D., by email to nuckollg@
ninds.nih.gov or (301) 496–5745.
SUPPLEMENTARY INFORMATION: The
Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory
committee established in accordance
with the Muscular Dystrophy
Community Assistance, Research, and
Education Amendments of 2001 (MD–
CARE Act; Pub. L. 107–84). The MD–
CARE Act was reauthorized in 2008 by
Public Law 110–361, and again in 2014
by Public Law 113–166. The MD–CARE
Act specifies that the committee
membership be composed of 2⁄3
governmental agency representatives
and 1⁄3 public members. We are seeking
nominations for two non-federal public
members at this time, due to turnover of
committee membership. Nominations
will be accepted between May 7 and
June 7, 2021.
Who is Eligible: Nominations are
encouraged for new or reappointment of
non-federal public members who can
provide the public and/or patient
perspectives to discussions of issues
considered by the Committee. Selfnominations and nominations of other
individuals are both permitted. Only
one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-federal
public members may be selected from
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:49 May 05, 2021
Jkt 253001
the pool of submitted nominations or
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
communities. Nominations are
especially encouraged from leaders or
representatives of muscular dystrophy
research, advocacy, or service
organizations, as well as individuals
with muscular dystrophy or their
parents or guardians. In accordance
with White House Office of
Management and Budget guidelines (FR
Doc. 2014–19140), federally-registered
lobbyists are not eligible.
Committee Composition: The
Department strives to ensure that the
membership of HHS Federal advisory
committees is fairly balanced in terms of
points of view represented and the
committee’s function. Every effort is
made to ensure that the views of all
genders, all ethnic and racial groups,
and people with disabilities are
represented on HHS Federal advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
geographic diversity in the composition
of the Committee. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Requests for
reasonable accommodation to enable
participation on the Committee should
be indicated in the nomination
submission.
Member Terms: Non-Federal public
members of the Committee serve for a
term of 3 years and may serve for an
unlimited number of terms if
reappointed. Members may serve after
the expiration of their terms, until their
successors have taken office.
Meetings and Travel: As specified by
Public Law 113–166, the MDCC ‘‘shall
meet no fewer than two times per
calendar year.’’ Travel expenses are
provided for non-federal public
Committee members to facilitate
attendance at in-person meetings.
Members are expected to make every
effort to attend all full committee
meetings, twice per year, either in
person or via remote access.
Participation in relevant subcommittee,
working and planning group meetings,
and workshops, is also encouraged.
Submission Instructions and
Deadline: Nominations are due by 5:00
p.m. EDT on June 7, 2021, and should
be sent to Glen Nuckolls, Ph.D., by
email to nuckollg@ninds.nih.gov.
Nominations must include contact
information for the nominee, a current
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
curriculum vitae or resume of the
nominee, and a paragraph describing
the qualifications of the person to
represent some portion(s) of the
muscular dystrophy research, advocacy,
and/or patient care communities.
More information about the MDCC is
available at https://mdcc.nih.gov/.
Dated: April 28, 2021.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
[FR Doc. 2021–09562 Filed 5–5–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Initial Review
Group; Genome Research Review Committee
GNOM.
Date: June 10, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 300, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Ken D. Nakamura, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817, 301–
402–0838.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: May 3, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–09583 Filed 5–5–21; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\06MYN1.SGM
06MYN1
]]>Agencies
[Federal Register Volume 86, Number 86 (Thursday, May 6, 2021)]
[Notices]
[Page 24408]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-09562]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Secretary, Muscular Dystrophy Coordinating
Committee Call for Committee Membership Nominations
AGENCY: National Institutes of Health, Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Office of the Secretary of the Department of Health and
Human Services (HHS) is seeking nominations for two individuals to
serve as non-federal public members on the Muscular Dystrophy
Coordinating Committee.
DATES: Nominations are due by 5:00 p.m. EDT on June 7, 2021.
ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email
to [email protected].
FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to
[email protected] or (301) 496-5745.
SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory committee established in
accordance with the Muscular Dystrophy Community Assistance, Research,
and Education Amendments of 2001 (MD-CARE Act; Pub. L. 107-84). The MD-
CARE Act was reauthorized in 2008 by Public Law 110-361, and again in
2014 by Public Law 113-166. The MD-CARE Act specifies that the
committee membership be composed of \2/3\ governmental agency
representatives and \1/3\ public members. We are seeking nominations
for two non-federal public members at this time, due to turnover of
committee membership. Nominations will be accepted between May 7 and
June 7, 2021.
Who is Eligible: Nominations are encouraged for new or
reappointment of non-federal public members who can provide the public
and/or patient perspectives to discussions of issues considered by the
Committee. Self-nominations and nominations of other individuals are
both permitted. Only one nomination per individual is required.
Multiple nominations for the same individual will not increase
likelihood of selection. Non-federal public members may be selected
from the pool of submitted nominations or other sources as needed to
meet statutory requirements and to form a balanced committee that
represents the diversity within the muscular dystrophy communities.
Nominations are especially encouraged from leaders or representatives
of muscular dystrophy research, advocacy, or service organizations, as
well as individuals with muscular dystrophy or their parents or
guardians. In accordance with White House Office of Management and
Budget guidelines (FR Doc. 2014-19140), federally-registered lobbyists
are not eligible.
Committee Composition: The Department strives to ensure that the
membership of HHS Federal advisory committees is fairly balanced in
terms of points of view represented and the committee's function. Every
effort is made to ensure that the views of all genders, all ethnic and
racial groups, and people with disabilities are represented on HHS
Federal advisory committees and, therefore, the Department encourages
nominations of qualified candidates from these groups. The Department
also encourages geographic diversity in the composition of the
Committee. Appointment to this Committee shall be made without
discrimination on the basis of age, race, ethnicity, gender, sexual
orientation, disability, and cultural, religious, or socioeconomic
status. Requests for reasonable accommodation to enable participation
on the Committee should be indicated in the nomination submission.
Member Terms: Non-Federal public members of the Committee serve for
a term of 3 years and may serve for an unlimited number of terms if
reappointed. Members may serve after the expiration of their terms,
until their successors have taken office.
Meetings and Travel: As specified by Public Law 113-166, the MDCC
``shall meet no fewer than two times per calendar year.'' Travel
expenses are provided for non-federal public Committee members to
facilitate attendance at in-person meetings. Members are expected to
make every effort to attend all full committee meetings, twice per
year, either in person or via remote access. Participation in relevant
subcommittee, working and planning group meetings, and workshops, is
also encouraged.
Submission Instructions and Deadline: Nominations are due by 5:00
p.m. EDT on June 7, 2021, and should be sent to Glen Nuckolls, Ph.D.,
by email to [email protected].
Nominations must include contact information for the nominee, a
current curriculum vitae or resume of the nominee, and a paragraph
describing the qualifications of the person to represent some
portion(s) of the muscular dystrophy research, advocacy, and/or patient
care communities.
More information about the MDCC is available at https://mdcc.nih.gov/.
Dated: April 28, 2021.
Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke,
National Institutes of Health.
[FR Doc. 2021-09562 Filed 5-5-21; 8:45 am]
BILLING CODE 4140-01-P
